Alkem Rolls Out De Simone Blend as Gut-Health Demand Rises

Alkem Laboratories has introduced the original De Simone formulation to India, marking a strong move into the country’s fast-rising gut-health market.

The launch comes at a time when digestive disorders are climbing and consumer awareness around probiotics is quickly expanding.

Developed by Italian microbiologist Prof Claudio De Simone, this proprietary blend brings together eight synergistic bacterial strains that help restore microbiota balance and support a broad range of gastrointestinal conditions.

It is among the world’s most researched probiotic combinations, backed by over 80 clinical trials and 200 scientific publications, and is endorsed by major gastroenterology bodies across the US and Europe. Alkem has in-licensed the technology from Next Gen Pharma India.

Also Read: India's Innovative Therapies Set Global Standard at Low Cost

“With gut health becoming central to overall well-being, probiotics are emerging as a key therapeutic tool,” said Dr Vikas Gupta, CEO, Alkem. “Bringing DSS to India strengthens our gastrointestinal portfolio and reinforces our commitment to delivering evidence-based innovations to patients.” 

In a first for the Indian market, Alkem will offer the probiotic—branded DSS—in four strengths: 225 billion CFU sachet, 112.5 billion CFU capsule, 45 billion CFU capsule, and 10 billion CFU capsule. The company is the only player providing all four versions and holds exclusive rights for the newly introduced 225 billion and 10 billion CFU formats. The blend includes four Lactobacillus, three Bifidobacterium, and one Streptococcus strain, all freeze-dried to preserve stability and ensure targeted clinical impact.

DSS is indicated for Irritable Bowel Syndrome, Ulcerative Colitis, Pouchitis, Hepatic Encephalopathy, NAFLD, cirrhosis, Bacterial Vaginosis, and Antibiotic-Associated Diarrhea, and is also recommended during pregnancy. With the De Simone formulation now locally available, Alkem aims to strengthen its position in India’s expanding gastrointestinal therapy space.